Aurealis Pharma Completes Second Round of Seed Financing to Advance Its Immune Microenvironment Modulation Technology


Aurealis Pharma, a private biopharmaceutical company focused on chronic inflammation and oncology, today announced the closing of 1.4MEUR second seed stage funding provided by private shareholders, Aloitusrahasto Vera Oy, KYS Invest Oy, and Tekes –the Finnish Funding Agency for Innovation.

”This financing will enable the second phase in our two-year-plan allowing us to develop our lead products into non-clinical proof-of-concept in chronic inflammatory wounds and to validate our Live Biotherapeutic Products technology in general” stated Thomas Wirth, CSO of Aurealis Pharma.

“Aurealis Pharma team has demonstrated its ability to execute programs quickly and create value in a capital efficient way. That combined with their exceptional technology triggered our continuedcommitment” said Matti Eskelinen, Investment Manager of Aloitusrahasto Vera Oy.

“We are grateful to have early investors who share our vision and can help us quickly advance our technology towards the clinic” added Juha Yrjänheikki, CEO of Aurealis Pharma.

Aurealis Pharma is a Kuopio, Finland based privately-held biopharmaceutical company focusing on developing proprietary technology to effectively, safely and economically modulate and re-educate the distorted host immune microenvironment to proper statein chronic inflammation and cancer.

Eero Lukin
comments powered by Disqus